Comparison of level of NKG2D ligands between normal and tumor tissue using multiplex RT-PCR

Cancer Investigation

Volumn 25, Issue 5, 2007, Pages 299-307

  Park, Soon Won ^a   Bae, Jae Ho ^b   Kim, Sang Doo ^b   Son, Young Ok ^a   Kim, Joo Young ^b   Park, Hyun Jin ^b   Lee, Chang Hun ^b   Park, Do Youn ^b   Kim, Jee Yeon ^b   Lee, Min Ki ^b   Chung, Byung Seon ^b   Kim, Sun Hee ^b,c   Kang, Chi Dug ^b,c  

^a Binex Co Ltd   (South Korea)

^b Pusan National University School of Medicine   (South Korea)

^c Pusan National University School of Medicine   (South Korea)

Author keywords

Cancer tissues; Multidrug resistant metastatic cells; Multiplex RT PCR; NKG2D ligands

Indexed keywords

LIGAND; NATURAL KILLER CELL RECEPTOR NKG2D; NATURAL KILLER CELL RECEPTOR NKG2D LIGAND; RNA; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER TISSUE; CELL STRAIN MCF 7; CONTROLLED STUDY; DIAGNOSTIC KIT; DIAGNOSTIC VALUE; GASTROINTESTINAL TUMOR; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MALE; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION;

CELL LINE, TUMOR; DNA PRIMERS; FLOW CYTOMETRY; GASTROINTESTINAL NEOPLASMS; HUMANS; KILLER CELLS, NATURAL; LIGANDS; NEOPLASM METASTASIS; NEOPLASMS; RECEPTORS, IMMUNOLOGIC; REFERENCE VALUES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM;

EID: 34547507350     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900701208824     Document Type: Article

References (31)

1. Parish C.R. Cancer immunotherapy: the past, the present and the future. Immunol. Cell Biol. 2003, 81 (2), 106-113.
2. Offringa R.; van der Burg S.H.; Ossendorp F.; Toes R.E.; Melief C.J. Design and evaluation of antigen-specific vaccination strategies against cancer. Curr. Opin. Immunol. 2000, 12 (5), 576-582.
3. Garrido F.; Ruiz-Cabello F.; Cabrera T.; Perez-Villar J.J.; Lopez-Botet M.; Duggan-Keen M.; Stern P.L. Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol. Today 1997, 18 (2), 89-95.
4. Karre K.; Ljunggren H.G.; Piontek G.; Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986, 319 (6055), 675-678.
5. Farag S.S.; Fehniger T.A.; Becknell B.; Blaser B.W.; Caligiuri M.A. Newdirections in natural killer cell-based immunotherapy of human cancer. Expert. Opin. Biol. Ther. 2003, 3 (2), 237-250.
6. Moretta A.; Bottino C.; Vitale M.; Pende D.; Cantoni C.; et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu. Rev. Immunol. 2001, 19, 197-223.
7. Malnati M.S.; Lusso P.; Ciccone E.; Moretta A.; Moretta L.; Long E.O. Recognition of virus-infected cells by natural killer cell clones is controlled by polymorphic target cell elements. J. Exp. Med. 1993, 178 (3), 961-969.
8. Routes J.M. IFN increases class I MHC antigen expression on adenovirus-infected human cells without inducing resistance to natural killer cell killing. J. Immunol. 1992, 149 (7), 2372-2377.
9. Bauer S.; Groh V.;Wu J.; Steinle A.; Phillips J.H.; Lanier L.L.; Spies T. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999, 285 (5428), 727-729.
10. Cosman D.; Mullberg J.; Sutherland C.L.; Chin W.; Armitage R.; et al. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity 2001, 14 (2), 123-133.
11. Smyth M.J.; Swann J.; Cretney E.; Zerafa N.; Yokoyama W.M.; Hayakawa Y. NKG2D function protects the host from tumor initiation. J. Exp. Med. 2005, 202 (5), 583-588.
12. Vivier E.; Tomasello E.; Paul P. Lymphocyte activation via NKG2D: towards a new paradigm in immune recognition? Curr. Opin. Immunol. 2002, 14 (3), 306-311.
13. Watzl C. The NKG2D receptor and its ligands-recognition beyond the "missing self"? Microbes Infect. 2003, 5 (1), 31-37.
14. Long E.O.; Rajagopalan S. Stress signals activate natural killer cells. J. Exp. Med. 2002, 196 (11), 1399-1402.
15. Rosenberg S.A.; Lotze M.T.; Muul L.M.; Leitman S.; Chang A.E.; et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N. Engl. J. Med. 1985, 313 (23), 1485-1492.
16. Gonzalez S.; Groh V.; Spies T. Immunobiology of human NKG2D and its ligands. Curr. Top. Microbiol. Immunol. 2006, 298, 121-138.
17. Bahram S.; Bresnahan M.; Geraghty D.E.; Spies T. A second lineage of mammalian major histocompatibility complex class I genes. Proc. Natl. Acad. Sci. USA 1994, 91 (14), 6259-6263.
18. Groh V.; Bahram S.; Bauer S.; Herman A.; Beauchamp M.; Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 1996, 93 (22), 12445-12450.
19. Pende D.; Rivera P.; Marcenaro S.; Chang C.C.; Biassoni R.; et al. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res. 2002, 62 (21), 6178-6186.
20. Jinushi M.; Takehara T.; Tatsumi T.; Kanto T.; Groh V.; et al. Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid. Int. J. Cancer. 2003, 104 (3), 354-361.
21. Morikawa K.; Walker S.M.; Nakajima M.; Pathak S.; Jessup J.M.; Fidler I.J. Influence of organ environment on the growth, selection, and metastasis of human colon carcinoma cells in nude mice. Cancer Res. 1988, 48 (23), 6863-6871.
22. Kaighn M.E.; Narayan K.S.; Ohnuki Y.; Lechner J.F.; Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 1979, 17 (1), 16-23.
23. Soule H.D.; Vazguez J.; Long A.; Albert S.; Brennan M. A human cell line from a pleural effusion derived from a breast carcinoma. J. Natl. Cancer Inst. 1973, 51 (5), 1409-1416.
24. Vickers P.J.; Dickson R.B.; Shoemaker R.; Cowan K.H. Amultidrug-resistant MCF-7 human breast cancer cell line which exhibits cross-resistance to antiestrogens and hormone-independent tumor growth in vivo. Mol. Endocrinol. 1988, 2 (10), 886-892.
25. Lee P.D.; Sladek R.; Greenwood C.M.; Hudson T.J. Control genes and variability: absence of ubiquitous reference transcripts in diverse mammalian expression studies. Genome Res. 2002, 12 (2), 292-297.
26. Welte S.A.; Sinzger C.; Lutz S.Z.; Singh-Jasuja H.; Sampaio K.L.; et al. Selective intracellular retention of virally induced NKG2D ligands by the human cytomegalovirus UL16 glycoprotein. Eur. J. Immunol. 2003, 33 (1), 194-203.
27. Higuchi R.; Fockler C.; Dollinger G.; Watson R. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (NY). 1993, 11 (9), 1026-1030.
28. Klein D. Quantification using real-time PCR technology: applications and limitations. Trends Mol. Med. 2002, 8 (6), 257-260.
29. Skrypina N.A.; Timofeeva A.V.; Khaspekov G.L.; Savochkina L.P.; Beabealashvilli R. Total RNA suitable for molecular biology analysis. J. Biotechnol. 2003, 105 (1-2), 1-9.
30. Wagsater D.; Dimberg J.; Hugander A.; Sirsjo A.; Ghaderi M. Analysis of MICA gene transcripts in human rectal cancers. Anticancer Res. 2003, 23 (3B), 2525-2529.
31. Pende D.; Cantoni C.; Rivera P.; Vitale M.; Castriconi R.; et al. Role of NKG2D in tumor cell lysis mediated by human NK cells: cooperation with natural cytotoxicity receptors and capability of recognizing tumors of nonepithelial origin. Eur. J. Immunol. 2001, 31 (4), 1076-1086.